Diana Wouters

Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.

Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products.

Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.

C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor.

Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients.

High-throughput analysis of the C4 polymorphism by a combination of MLPA and isotype-specific ELISA's.

Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory disease.

Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1.

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients.

Differential effect of drug interference in immunogenicity assays.

A tick mannose-binding lectin inhibitor interferes with the vertebrate complement cascade to enhance transmission of the lyme disease agent.

The bacteria binding glycoprotein salivary agglutinin (SAG/gp340) activates complement via the lectin pathway.

Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing.

C1-esterase inhibitor protects against early vein graft remodeling under arterial blood pressure.

Prolonged C1 inhibitor administration improves local healing of burn wounds and reduces myocardial inflammation in a rat burn wound model.

Crosstalk between Toll like receptors and C5a receptor in human monocyte derived DCs suppress inflammatory cytokine production.

IgG4 production against adalimumab during long term treatment of RA patients.

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation.

Blood plasma inflammation markers during epileptogenesis in post-status epilepticus rat model for temporal lobe epilepsy.

C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia.

The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab.

IgG antibodies in food allergy influence allergen-antibody complex formation and binding to B cells: a role for complement receptors.

Inhibition of the Classical and Lectin Pathway of the Complement System by Recombinant LAIR-2.

Evaluating the efficacy of subcutaneous C1-esterase inhibitor administration for use in rat models of inflammatory diseases.

Plasma-derived mannose-binding lectin shows a direct interaction with C1-inhibitor.

Antibodies to IgG4 hinge can be found in Rheumatoid Arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation.